Outlook Therapeutics Inc (OTLK)
NASDAQHealth CareBiotechnologySnapshot 2026-10-29
$0.47-5.15%
Close 2026-10-30 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-10-29
Research Workspace
Put OTLK beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisManagement screens weak on capital allocation, earnings delivery, the balance sheet, market reaction to earnings.
View ManagementThis stock is highly volatile — it swings about 4% on a typical day and fell roughly 92% in its worst 12-month stretch.
View RiskOTLK’s case rests on steady recent financial performance and a supportive sector, despite unprofitability and high risk. Its latest reported quarter was inline, with non-GAAP EPS of -0.09; revenue growth data is unavailable. The shares trade at 2× sales versus a 10× peer median, below their 3× historical multiple. The price is roughly in line with the growth we forecast. A next-quarter miss is a concrete risk, with our model placing its probability near 45%. Frequent disruptive corporate change adds risk to the case. Peer multiples imply a price about 85% above where it trades; our read remains intact. This read is provisional.
Trailing returns as of 2026-10-30. OTLK is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 4 analysts currently covering OTLK (as of Oct 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
Continue this research
Compare OTLK with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| OTLK Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 2 valuation methods, at three horizons. As of 2026-10-30. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put OTLK next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Threatens: Commercial launch and expansion of LYTENAVA in the U.S.
Launch access issues could hinder LYTENAVA's commercial success.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-30. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 10% on quality vs scored peers
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Advances: Commercial launch and expansion of LYTENAVA in the U.S.
CEO's discussion indicates progress on commercial launch.
Advances: Commercial launch and expansion of LYTENAVA in the U.S.
Better-than-expected EPS indicates strong commercial performance.
Advances: Raise capital through equity offerings to support operations
CEO investment signals confidence in company prospects.
Advances: Commercial launch and expansion of LYTENAVA in Europe
Targets significant sales growth for LYTENAVA by 2030.
Advances: Raise capital through equity offerings
Capital raised supports growth initiatives and operational funding.
Advances: Manage capital through debt issuance
Raising capital supports management's objective on capital allocation.
Downgrade indicates potential challenges to financial performance.